AKERO THERAPEUTICS INC (AKRO)

Company Profile

Akero Therapeutics, Inc. is a clinical-stage company, which engages in the development of treatments for patients with serious metabolic diseases. The company is headquartered in South San Francisco, California and currently employs 58 full-time employees. The company went IPO on 2019-06-20. The firm is developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, including metabolic dysfunction-associated steatohepatitis (MASH), a disease without any approved therapies. Efruxifermin (EFX), is its lead product candidate for MASH, which is being evaluated in the ongoing phase IIb SYMMETRY, phase III SYNCHRONY Histology, and phase III SYNCHRONY real-world studies. The phase III SYNCHRONY program builds on the results of two phase IIb clinical trials, the HARMONY study in patients with pre-cirrhotic MASH and the SYMMETRY study in patients with cirrhosis due to MASH. EFX is an analog of fibroblast growth factor 21 (FGF21), which is an endogenously expressed hormone that protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. EFX is designed to offer convenient once-weekly dosing.

Company Info

AKERO THERAPEUTICS INC

601 Gateway Boulevard, Suite 350

South San Francisco CALIFORNIA 94080

P: 16504876488

CEO: Andrew Cheng

Employees: 61

Website: https://akerotx.com/